China Adrenal Disease Registry

Pheochromocytoma Clinical Trial

— CASE  

Official title:

China Adrenal Disease Registry Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04890444
• Other study ID #: Ruijin-adrenal01
• Status: Recruiting
• Start date: June 1, 2021
• Est. completion date: April 30, 2026

Study information

• Verified date: January 2022
• Source: Shanghai Jiao Tong University School of Medicine
• Contact: shouyue SUN, MD
• Phone: 18121263206
• Email: ssy10926[@]rjh.com.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Epidemiologic studies have revealed a tremendous increase in the prevalence of adrenal associated disease and related mortality worldwide. In order to meet all the therapeutic challenges in adrenal disease in China, CASE was founded in 2020. The objective of CASE is to launch an adrenal disease management model based on the Internet health information platform which allows the application and evaluation of adrenal disease treatment strategies at multiple centers. The proprietary electronic medical database will help the dynamic big-data analysis in epidemiology of adrenal disease, diagnosis, and treatment.

Description:

In order to meet all the challenges in the diagnosis and treatment of adrenal diseases in China, CASE was founded in 2020. With advanced medical equipment and Internet of Things (IoT) technology, CASE is committed to creating an online and offline integrated solution for adrenal disease, and for the entire spectrum of adrenal disease, to achieve a more convenient and precise model of care for patients, aiming to establish a platform with diagnosis and treatment of adrenal disease and their long-term follow-up. It allows the application and evaluation of treatment strategies at these centers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: April 30, 2026
• Est. primary completion date: April 30, 2026
• Gender: All
• Age group: 16 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age = 16 years old and = 75 years

2. Patients diagnosed with adrenal associated diseases, including cushing syndrome, primary aldosteronism, primary hypoadrenalism, congenital adrenal hyperplasia and adrenal adenomas, incidentalomas, and carcinomas, pheochromocytoma, etc.

3. Provide written informed consent

4. Satisfactory compliance

Exclusion Criteria:

1. Patients with significantly reduced life expectancy (less than 2 years)

2. With Drug abuse

3. With AIDS or syphilis or infectious diseases such as viral tuberculosis in active phase at enrollment

Related Conditions & MeSH terms

• Adenoma
• Adrenal Adenoma
• Adrenal Carcinoma
• Adrenal Hyperplasia, Congenital
• Adrenal Incidentaloma
• Adrenocortical Adenoma
• Adrenogenital Syndrome
• Aldosteronism
• Congenital Adrenal Hyperplasia
• Cushing Syndrome
• Hyperaldosteronism
• Hyperplasia
• Pheochromocytoma

Locations

Country	Name	City	State
China	Endocrinology	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Jiao Tong University School of Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of adrenal diseases in China		through study completion, an average of 1 year
Primary	Number of participants with complication of adrenal diseases in China		through study completion, an average of 1 year
Secondary	concentration of aldosterone		through study completion, an average of 1 year
Secondary	concentration of cortisol		through study completion, an average of 1 year
Secondary	concentration of urine cortisol		through study completion, an average of 1 year
Secondary	concentration of androstenedione		through study completion, an average of 1 year
Secondary	concentration of adrenocorticotropic hormone		through study completion, an average of 1 year
Secondary	concentration of 17-hydroxyprogesterone		through study completion, an average of 1 year
Secondary	concentration of metanephrines		through study completion, an average of 1 year
Secondary	changes in adrenal CT		through study completion, an average of 1 year
Secondary	percentage of hypoadrenalism		through study completion, an average of 1 year
Secondary	Mental health status	The symptom checklist-90 will be used to evaluate the changes of participants' psychological state through study completion from 10 aspects, including somatization, obsessive-compulsive symptoms, interpersonal sensitivity, depression, anxiety, hostility, terror, paranoia, psychotic and others.	through study completion, an average of 1 year